What impact does disease rarity have on rare and orphan drug pricing?
As more pharmaceutical companies develop and launch drugs to treat rare diseases, reimbursement decisions indicate that payers are looking at a range of...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
As more pharmaceutical companies develop and launch drugs to treat rare diseases, reimbursement decisions indicate that payers are looking at a range of...
In this first article of a three-part PharmaPhorum series exploring pricing in Europe, we discuss the role disease rarity plays in reimbursement decisions...